Benzinga | Oct 5, 2021 09:37AM EDT

Piper Sandler Maintains Overweight on Biohaven Pharma Hldgs, Raises Price Target to $156

Piper Sandler analyst Christopher Raymond maintains Biohaven Pharma Hldgs (NYSE:BHVN) with a Overweight and raises the price target from $140 to $156.